BOOK
Contemporary Management and Controversies of Sarcoma, An Issue of Surgical Oncology Clinics of North America, E-Book
(2016)
Additional Information
Book Details
Abstract
This issue of Surgical Oncology Clinics of North America, guest edited by Dr. Chandrajit P. Raut, is devoted to Sarcomas. Dr. Raut has assembled expert authors to review the following topics: Sarcoma: Histologic Subtypes and Changes in the Recent WHO Classification; Distinguishing Radiologic Characteristics of Sarcoma Histologic Subtypes; Extremity Soft Tissue Sarcoma: Tailoring Resection to Histologic Subtype; Retroperitoneal Sarcoma: Fact, Opinion, and Controversy; Breast Sarcoma; Management of Sarcoma Metastases to the Lung; Gastrointestinal Stromal Tumor; Liposarcoma: Surgical Management and Future Targeted Therapy; Myxofibrosarcoma; Malignant Peripheral Nerve Sheath Tumor; Desmoid Fibromatosis: Evolving Treatment Standards; Dermatofibrosarcoma Protuberans: Surgery v. Mohs; Radiation Therapy: Indications and Controversies for Neoadjuvant Therapy, Adjuvant Therapy, IORT, and Brachytherapy; Chemotherapy: Does Neoadjuvant or Adjuvant Therapy Improve Outcomes?; and more!
Table of Contents
| Section Title | Page | Action | Price |
|---|---|---|---|
| Front Cover | Cover | ||
| ContemporaryManagement andControversies of Sarcoma | i | ||
| Copyright\r | ii | ||
| Contributors | iii | ||
| CONSULTING EDITOR | iii | ||
| EDITOR | iii | ||
| AUTHORS | iii | ||
| Contents | vii | ||
| Foreword: Sarcomas 2016\r | vii | ||
| Preface\x0B | vii | ||
| Refinements in Sarcoma Classification in the Current 2013 World Health Organization Classification of Tumours of Soft Tissu ... | vii | ||
| Imaging in Soft Tissue Sarcomas: Current Updates\r | vii | ||
| Extremity Soft Tissue Sarcoma: Tailoring Resection to Histologic Subtype\r | vii | ||
| Retroperitoneal Sarcoma: Fact, Opinion, and Controversy\r | viii | ||
| Sarcomas of the Breast with a Spotlight on Angiosarcoma and Cystosarcoma Phyllodes\x0B | viii | ||
| Management of Sarcoma Metastases to the Lung\r | viii | ||
| Combined Therapy of Gastrointestinal Stromal Tumors\r | viii | ||
| Liposarcoma: Multimodality Management and Future Targeted Therapies\r | ix | ||
| Myxofibrosarcoma\r | ix | ||
| Malignant Peripheral Nerve Sheath Tumor\r | ix | ||
| Desmoid-Type Fibromatosis: Evolving Treatment Standards\r | ix | ||
| Dermatofibrosarcoma Protuberans: Wide Local Excision Versus Mohs Micrographic Surgery\r | x | ||
| Radiation Therapy for Soft Tissue Sarcoma: Indications and Controversies for Neoadjuvant Therapy, Adjuvant Therapy, Intraop ... | x | ||
| Chemotherapy: Does Neoadjuvant or Adjuvant Therapy Improve Outcomes?\r | x | ||
| SURGICAL ONCOLOGY\rCLINICS OF NORTH AMERICA\r\r | xii | ||
| FORTHCOMING ISSUES | xii | ||
| January 2017 | xii | ||
| April 2017 | xii | ||
| July 2017 | xii | ||
| RECENT ISSUES | xii | ||
| July 2016 | xii | ||
| April 2016 | xii | ||
| January 2016 | xii | ||
| Foreword:\rSarcomas 2016 | xiii | ||
| Preface | xv | ||
| SITE-SPECIFIC SARCOMA MANAGEMENT | xv | ||
| HISTOLOGY-SPECIFIC MANAGEMENT | xvi | ||
| NEOADJUVANT AND ADJUVANT THERAPY | xvi | ||
| Refinements in Sarcoma Classification in the Current 2013 World Health Organization Classification of Tumours of Soft Tissu ... | 621 | ||
| Key points | 621 | ||
| INTRODUCTION | 621 | ||
| TUMORS OF SOFT TISSUE | 622 | ||
| Adipocytic Tumors | 622 | ||
| Fibroblastic/Myofibroblastic Tumors | 623 | ||
| So-Called Fibrohistiocytic Tumors | 624 | ||
| Smooth Muscle Tumors | 624 | ||
| Pericytic (Perivascular) Tumors | 624 | ||
| Skeletal Muscle Tumors | 625 | ||
| Vascular Tumors | 625 | ||
| Chondro-Osseous Tumors | 627 | ||
| Gastrointestinal Stromal Tumors | 627 | ||
| Nerve Sheath Tumors | 629 | ||
| Tumors of Uncertain Differentiation | 629 | ||
| Undifferentiated/Unclassified Sarcomas | 630 | ||
| TUMORS OF BONE | 631 | ||
| Chondrogenic Tumors | 631 | ||
| Osteogenic Tumors | 632 | ||
| Fibrogenic Tumors | 632 | ||
| Fibrohistiocytic Tumors | 632 | ||
| Ewing Sarcoma | 632 | ||
| Osteoclastic Giant Cell–Rich Tumors | 633 | ||
| Notochordal Tumors | 633 | ||
| Vascular Tumors | 633 | ||
| Hematopoietic Neoplasms and Myogenic, Lipogenic, and Epithelial Tumors | 633 | ||
| Tumors of Undefined Neoplastic Nature | 633 | ||
| Undifferentiated High-Grade Pleomorphic Sarcoma | 633 | ||
| SUMMARY | 634 | ||
| REFERENCES | 634 | ||
| Imaging in Soft Tissue Sarcomas | 645 | ||
| Key points | 645 | ||
| INTRODUCTION | 645 | ||
| SPECIFIC HISTOLOGIC SUBTYPES BASED ON THE WORLD HEALTH ORGANIZATION CLASSIFICATION | 646 | ||
| Adipocytic Tumors: Liposarcomas | 646 | ||
| Atypical lipomatous tumor/well-differentiated liposarcoma | 646 | ||
| Dedifferentiated liposarcoma | 647 | ||
| Myxoid liposarcoma | 647 | ||
| Pleomorphic liposarcoma | 649 | ||
| FIBROBLASTIC/MYOFIBROBLASTIC TUMORS | 650 | ||
| Dermatofibrosarcoma Protuberans | 650 | ||
| Myxofibrosarcoma | 651 | ||
| Smooth Muscle Tumors | 652 | ||
| SKELETAL MUSCLE TUMORS | 653 | ||
| Rhabdomyosarcomas | 653 | ||
| Vascular Tumors | 654 | ||
| Angiosarcoma of soft tissue | 654 | ||
| NERVE SHEATH TUMORS | 655 | ||
| TUMORS OF UNCERTAIN DIFFERENTIATION | 656 | ||
| Synovial Sarcoma | 656 | ||
| Alveolar Soft Part Sarcoma | 657 | ||
| Extraskeletal Ewing Sarcoma | 658 | ||
| Extraskeletal Osteosarcoma | 659 | ||
| Aggressive Angiomyxoma | 660 | ||
| Desmoplastic Small Round Cell Tumor | 660 | ||
| Solitary Fibrous Tumor | 661 | ||
| Gastrointestinal Stromal Tumor | 663 | ||
| UNDIFFERENTIATED/UNCLASSIFIED SARCOMAS | 663 | ||
| Intraabdominal/Retroperitoneal Sarcomas | 663 | ||
| Extremity Soft Tissue Sarcoma | 677 | ||
| Key points | 677 | ||
| INTRODUCTION | 677 | ||
| HISTOLOGY AS A PROGNOSTIC FACTOR | 678 | ||
| HISTOLOGIC SUBTYPES WITHIN SOFT TISSUE SARCOMA | 680 | ||
| BIOPSY AND INTERPRETATION | 681 | ||
| FROZEN SECTION CONSIDERATIONS | 683 | ||
| SOFT TISSUE SARCOMAS SUBTYPE GUIDING RESECTION MARGINS | 684 | ||
| PLANNED POSITIVE MARGINS | 686 | ||
| SPECIAL CONSIDERATIONS WITH SPECIFIC SARCOMA SUBTYPES | 688 | ||
| SUMMARY | 692 | ||
| REFERENCES | 693 | ||
| Retroperitoneal Sarcoma | 697 | ||
| Key points | 697 | ||
| FACT | 697 | ||
| Diagnostic Challenges of Retroperitoneal Sarcomas | 698 | ||
| Management of Primary Retroperitoneal Sarcomas | 700 | ||
| Outcomes and Recurrence in Retroperitoneal Sarcomas | 703 | ||
| OPINION | 704 | ||
| Are Diagnostic Biopsies Standard of Care in Patients with Retroperitoneal Sarcomas? | 704 | ||
| Retroperitoneal Sarcomas Should Be Managed at Expert High-Volume Multidisciplinary Centers | 704 | ||
| Adjuvant Radiotherapy Should Be Given Preoperatively if at All | 705 | ||
| Management of Recurrent Disease | 705 | ||
| CONTROVERSY | 706 | ||
| Role of Extended Resection for Retroperitoneal Sarcomas | 706 | ||
| Role of Radiotherapy | 706 | ||
| Role of Chemotherapy | 707 | ||
| Quality of Life and Survivorship | 707 | ||
| SUMMARY | 707 | ||
| REFERENCES | 707 | ||
| Sarcomas of the Breast with a Spotlight on Angiosarcoma and Cystosarcoma Phyllodes | 713 | ||
| Key points | 713 | ||
| INTRODUCTION | 713 | ||
| SUBTYPES AND RISK FACTORS | 713 | ||
| DIAGNOSIS AND STAGING | 714 | ||
| TREATMENT | 714 | ||
| TALE OF 2 BREAST SARCOMAS | 716 | ||
| Cystosarcoma Phyllodes | 716 | ||
| Angiosarcoma | 717 | ||
| REFERENCES | 718 | ||
| Management of Sarcoma Metastases to the Lung | 721 | ||
| Key points | 721 | ||
| INTRODUCTION | 721 | ||
| PROGNOSTIC FACTORS | 722 | ||
| Histology | 723 | ||
| Disease-Free Interval | 723 | ||
| Number of Metastatic Foci | 723 | ||
| Completeness of Resection | 723 | ||
| Response to Chemotherapy | 725 | ||
| PREOPERATIVE EVALUATION | 725 | ||
| Preoperative Imaging | 725 | ||
| Preoperative Pulmonary Testing | 726 | ||
| Timing of Surgery | 726 | ||
| SURGICAL TECHNIQUE AND MANAGEMENT | 726 | ||
| Open Technique | 726 | ||
| Video-Assisted Thoracoscopic Surgery | 726 | ||
| Extent of Resection | 727 | ||
| Lymph Node Sampling | 727 | ||
| ADJUNCTIVE THERAPIES | 728 | ||
| Whole Lung Irradiation | 728 | ||
| Radiofrequency Ablation | 728 | ||
| Stereotactic Body Radiation Therapy | 728 | ||
| LONG-TERM FOLLOW-UP | 728 | ||
| COMPLEX MANAGEMENT | 728 | ||
| NOVEL THERAPY-ISOLATED LUNG PERFUSION | 729 | ||
| SUMMARY | 729 | ||
| REFERENCES | 730 | ||
| Combined Therapy of Gastrointestinal Stromal Tumors | 735 | ||
| Key points | 735 | ||
| INTRODUCTION: GASTROINTESTINAL STROMAL TUMORS GENERAL OVERVIEW | 735 | ||
| RISK ASSESSMENT OF PRIMARY GASTROINTESTINAL STROMAL TUMORS | 736 | ||
| PRIMARY LOCALIZED GASTROINTESTINAL STROMAL TUMORS | 738 | ||
| Neoadjuvant Strategy | 738 | ||
| Adjuvant Strategy | 742 | ||
| RECURRENT/METASTATIC GASTROINTESTINAL STROMAL TUMORS | 746 | ||
| SUMMARY | 751 | ||
| REFERENCES | 751 | ||
| Liposarcoma | 761 | ||
| Key points | 761 | ||
| INTRODUCTION | 761 | ||
| WELL-DIFFERENTIATED LIPOSARCOMA AND DEDIFFERENTIATED LIPOSARCOMA | 762 | ||
| Management of Primary Well-differentiated Liposarcoma and Dedifferentiated Liposarcoma in the Extremity | 762 | ||
| Management of Primary Well-differentiated Liposarcoma and Dedifferentiated Liposarcoma of the Retroperitoneum | 764 | ||
| Management of Recurrent Disease | 765 | ||
| Systemic Therapies for Well-differentiated Liposarcoma and Dedifferentiated Liposarcoma | 766 | ||
| MYXOID LIPOSARCOMA AND ROUND CELL LIPOSARCOMA | 767 | ||
| Multimodality Management of Primary Disease | 767 | ||
| Management of Recurrent Disease | 768 | ||
| PLEOMORPHIC LIPOSARCOMA | 769 | ||
| SUMMARY | 769 | ||
| ACKNOWLEDGMENTS | 770 | ||
| REFERENCES | 770 | ||
| Myxofibrosarcoma | 775 | ||
| Key points | 775 | ||
| INTRODUCTION: NATURE OF THE PROBLEM | 775 | ||
| PATHOPHYSIOLOGY | 776 | ||
| CYTOGENETICS AND MOLECULAR FINDINGS | 780 | ||
| CLINICAL PRESENTATION/EXAMINATION | 780 | ||
| DIAGNOSTIC PROCEDURES | 780 | ||
| THERAPEUTIC OPTIONS/SURGICAL TECHNIQUE | 781 | ||
| CLINICAL OUTCOMES | 783 | ||
| ROLE OF RADIATION | 785 | ||
| ROLE OF CHEMOTHERAPY | 785 | ||
| SUMMARY | 786 | ||
| REFERENCES | 786 | ||
| Malignant Peripheral Nerve Sheath Tumor | 789 | ||
| Key points | 789 | ||
| INTRODUCTION TO MALIGNANT PERIPHERAL NERVE SHEATH TUMOR | 789 | ||
| MOLECULAR PATHOGENESIS OF MALIGNANT PERIPHERAL NERVE SHEATH TUMOR | 791 | ||
| Neurofibromin 1 | 791 | ||
| Phosphatase and Tensin Homolog | 791 | ||
| Insulinlike Growth Factor 1 Receptor and Epidermal Growth Factor Receptor | 791 | ||
| Mitogen-Activated Protein Kinase | 792 | ||
| RADIOGRAPHIC DIAGNOSIS OF MALIGNANT PERIPHERAL NERVE SHEATH TUMOR | 792 | ||
| HISTOPATHOLOGIC DIAGNOSIS OF MALIGNANT PERIPHERAL NERVE SHEATH TUMOR | 793 | ||
| SURGICAL MANAGEMENT OF MALIGNANT PERIPHERAL NERVE SHEATH TUMOR | 795 | ||
| RADIATION THERAPY AND MALIGNANT PERIPHERAL NERVE SHEATH TUMOR | 797 | ||
| SYSTEMIC THERAPY AND MALIGNANT PERIPHERAL NERVE SHEATH TUMOR | 797 | ||
| CURRENT AND COMPLETED CLINICAL TRIALS OF TARGETED AGENTS | 798 | ||
| OUTCOMES OF MALIGNANT PERIPHERAL NERVE SHEATH TUMOR | 798 | ||
| SUMMARY | 799 | ||
| ACKNOWLEDGMENTS | 799 | ||
| REFERENCES | 799 | ||
| Desmoid-Type Fibromatosis | 803 | ||
| Key points | 803 | ||
| INTRODUCTION | 803 | ||
| Definition | 803 | ||
| PATHOPHYSIOLOGY AND EMERGING BIOLOGICAL INSIGHTS | 804 | ||
| Adenomatous Poliposis Coli Gene | 804 | ||
| β-Catenin | 804 | ||
| β-Catenin Mutations and Beyond | 805 | ||
| Gene Profiles | 807 | ||
| ETIOLOGY | 807 | ||
| Desmoid-Type Fibromatosis and Hormones | 807 | ||
| Desmoid-Type Fibromatosis and Scars | 807 | ||
| Progenitor Cell | 808 | ||
| PATIENT EVALUATION | 808 | ||
| Symptoms | 808 | ||
| Radiology | 808 | ||
| Pathology | 809 | ||
| EVOLVING ROLE OF SURGERY | 811 | ||
| Surgical Outcomes in Historical Series | 811 | ||
| Postsurgical Nomogram | 811 | ||
| Nonoperative Management | 813 | ||
| Stepwise Approach | 813 | ||
| PHARMACOLOGIC TREATMENT OPTIONS | 813 | ||
| ESTABLISHED TREATMENTS: NONSTEROIDAL ANTIINFLAMMATORY DRUGS, ANTIESTROGEN AGENTS, CYTOTOXIC CHEMOTHERAPY, IMATINIB | 816 | ||
| Antiinflammatory and Antiestrogen Agents | 816 | ||
| Hormone Therapy | 816 | ||
| Cytotoxic Chemotherapy | 816 | ||
| Imatinib Mesylate | 819 | ||
| NEW FRONTIERS: SUNITINIB, SORAFENIB, PAZOPANIB, GAMMA SECRETASE INHIBITOR, MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR | 819 | ||
| NONPHARMACOLOGIC TREATMENT OPTIONS | 820 | ||
| Radiotherapy | 820 | ||
| Cryoablation | 820 | ||
| Isolated Limb Perfusion | 820 | ||
| SURVEILLANCE RECOMMENDATIONS | 820 | ||
| ACKNOWLEDGMENTS | 821 | ||
| REFERENCES | 821 | ||
| Dermatofibrosarcoma Protuberans | 827 | ||
| Key points | 827 | ||
| INTRODUCTION | 827 | ||
| EPIDEMIOLOGY | 828 | ||
| CLINICAL PRESENTATION AND NATURAL HISTORY | 828 | ||
| PATHOLOGY | 828 | ||
| MOLECULAR BIOLOGY AND PATHOGENESIS | 830 | ||
| MANAGEMENT OF DERMATOFIBROSARCOMA PROTUBERANS: OVERVIEW | 831 | ||
| SURGICAL TREATMENT: WIDE LOCAL EXCISION | 831 | ||
| SURGICAL TREATMENT: MOHS MICROGRAPHIC SURGERY | 834 | ||
| WIDE LOCAL EXCISION OR MOHS MICROGRAPHIC SURGERY FOR DERMATOFIBROSARCOMA PROTUBERANS? | 835 | ||
| SUMMARY | 836 | ||
| REFERENCES | 837 | ||
| Radiation Therapy for Soft Tissue Sarcoma | 841 | ||
| Key points | 841 | ||
| INTRODUCTION | 841 | ||
| PATIENT EVALUATION OVERVIEW | 842 | ||
| SURGERY ALONE | 842 | ||
| RADIATION THERAPY OPTIONS | 843 | ||
| Definitive Radiation Therapy Without Surgery | 843 | ||
| Radiation Therapy Plus Surgery | 843 | ||
| External beam radiotherapy as adjuvant therapy for extremity sarcomas | 843 | ||
| External beam radiotherapy as adjuvant therapy for retroperitoneal sarcomas | 849 | ||
| Intraoperative radiation therapy for retroperitoneal sarcomas | 850 | ||
| Simultaneous integrated boost radiation for retroperitoneal sarcomas | 853 | ||
| Brachytherapy as adjuvant therapy for sarcomas | 853 | ||
| Radiation Therapy and Chemotherapy | 854 | ||
| RADIATION THERAPY COMPLICATIONS | 855 | ||
| SUMMARY | 857 | ||
| REFERENCES | 857 | ||
| Chemotherapy | 861 | ||
| Key points | 861 | ||
| INTRODUCTION | 861 | ||
| TREATMENT APPROACHES | 862 | ||
| BIOLOGICAL QUESTIONS IN SARCOMA CHEMOTHERAPY | 863 | ||
| CLINICAL TRIALS EVALUATING OUTCOMES | 864 | ||
| Doxorubicin Monotherapy Trials | 864 | ||
| Combination Doxorubicin-Ifosfamide Trials | 866 | ||
| Updated Meta-Analysis | 867 | ||
| Neoadjuvant Treatment | 867 | ||
| SUBTYPE-SPECIFIC ANALYSES | 868 | ||
| Synovial Sarcoma | 868 | ||
| Myxoid/Round Cell Liposarcoma | 869 | ||
| Undifferentiated Pleomorphic Sarcoma | 869 | ||
| TARGETED THERAPY/NOVEL AGENTS | 869 | ||
| Antiangiogenic Targeted Therapy | 869 | ||
| Trabedectin and Eribulin | 870 | ||
| SUMMARY | 870 | ||
| REFERENCES | 870 |